Skip to content
value.today

Sanofi: financial analysis

Ratios worked out from 10 fiscal years of Sanofi's statements, compared with 102 companies in Pharmaceutical.

Return on equity, 2025
10.7%
Pharmaceutical: -0.9%
Debt to equity, 2025
0.20×
Pharmaceutical: 0.66×

Sanofi scorecard#

Passes 5 of the 7 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year7.18 vs 4.79Diluted EPS 7.18 in fiscal 2025 against 4.79 the year before (report's currency).
    • ✗Net income higher than five years earlier$8.8 B$8.8 B in fiscal 2025 against $14.0 B in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 3
    • ✓Profitable in the newest year$8.8 BNet income $8.8 B in fiscal 2025.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%10.7%10.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 2
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • ✓Debt below equity0.2×Debt to equity 0.20 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec, wikidata), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • Free cash flow has been positive 5 years in a row.

Worth a look

  • Total debt rose 37% in the year, to $16.7 billion.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

5of 6(3 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseyes
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsno
  • Current ratio rosenot on file
  • No new shares issuedyes
  • Gross margin rosenot on file
  • Asset turnover rosenot on file

Profitability#

Sanofi: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Net margin—————-1.5%—
Return on equity10.7%7.4%7.2%11.2%9.5%-0.9%70%
Return on assets6.1%4.3%4.3%6.5%5.4%-1.3%76%

Growth#

Sanofi: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth—————7.3%—
Revenue growth, 3 years a year—————2.5%—
Revenue growth, 5 years a year—————6.0%—
Net income growth46.5%3.1%-33.6%19.6%-47.6%14.3%73%
Earnings per share growth49.9%3.1%-33.6%——12.4%79%

Financial strength#

Sanofi: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Debt to equity0.20×0.15×0.19×0.20×0.25×0.66×77%
Net debt$7.7 B$4.5 B$6.2 B$2.3 B$8.0 B$188 M27%
Interest cover——5.38×23.63×22.08×1.11×—
Current ratio——1.27×1.42×—1.98×—
Equity share of assets56.3%58.4%58.6%59.0%57.1%47.3%63%

Cash#

Sanofi: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$8.1 B$6.4 B$7.9 B$8.8 B$10.0 B$8 M91%
Cash conversion137.6%163.3%190.0%125.7%169.1%136.7%53%

Shareholder returns#

Sanofi: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Dividend payout——82.5%49.8%64.4%47.1%—
Change in share count——-0.0%0.0%—1.8%—

Efficiency#

Sanofi: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover—————0.55×—

How each figure is worked out#

Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Dividend payout
Dividends paid as a share of net income. Only when the year was profitable.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Sanofi's statements: annual reports filed with the SEC; Wikidata. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 102 companies in Pharmaceutical that Sanofi is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Sanofi